NCT06401889 Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
| NCT ID | NCT06401889 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Anatomic Stage 0 Breast Cancer AJCC v8 |
| Study Type | OBSERVATIONAL |
| Enrollment | 35 participants |
| Start Date | 2024-07-19 |
| Primary Completion | 2027-07-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 35 participants in total. It began in 2024-07-19 with a primary completion date of 2027-07-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates changes in skin quality and self-esteem among breast cancer patients who are initiating aromatase inhibitor therapy.
Eligibility Criteria
Inclusion Criteria: * \* Female ≥ 18 years * Postmenopausal women suitable to receive aromatase inhibitor as per physician's discretion * Histologically confirmed adenocarcinoma of the breast stage 0-III with estrogen receptor (ER) and/or progesterone receptor (PR) positive per American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guideline and any human epidermal growth factor receptor 2 (HER2) * Patients must not have received any prior chemotherapy or endocrine therapy for their current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included * Patients willing to avoid any facial procedures including facials, neurotoxin injections, fillers, or lasers during study period * Willing and able to provide consent Exclusion Criteria: * \* Patients who have previously taken AIs * Patients using prescription tretinoin, neurotoxin injections, fillers, facial lasers, microneedling, or facials within 6 months of study consent
Contact & Investigator
Leila M. Tolaymat, M.D.
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT06401889 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Anatomic Stage 0 Breast Cancer AJCC v8. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06401889 currently recruiting?
Yes, NCT06401889 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.
Where is the NCT06401889 trial being conducted?
This trial is being conducted at Jacksonville, United States.
Who is sponsoring the NCT06401889 clinical trial?
NCT06401889 is sponsored by Mayo Clinic. The principal investigator is Leila M. Tolaymat, M.D. at Mayo Clinic. The trial plans to enroll 35 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.